SINOPHARM GROUP (Germany) Top Insiders

X2S1 Stock  EUR 11.50  0.10  0.88%   
Examination of SINOPHARM GROUP's management performance can provide insight into the company performance.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in SINOPHARM GROUP 15ON. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Symbol  X2S1
Name  SINOPHARM GROUP 15ON
TypeStock
Country  
 Germany
Exchange  F

Information on SINOPHARM GROUP 15ON Leadership is currently not available.

If you believe this information is not accurate please let us know and we will check it out. Check all delisted instruments across multiple markets.

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

SINOPHARM GROUP Management Team Effectiveness

The company has return on total asset (ROA) of 0.0364 % which means that it generated a profit of $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1319 %, meaning that it generated $0.1319 on every $100 dollars invested by stockholders. SINOPHARM GROUP's management efficiency ratios could be used to measure how well SINOPHARM GROUP manages its routine affairs as well as how well it operates its assets and liabilities.

SINOPHARM GROUP Workforce Comparison

SINOPHARM GROUP 15ON is rated first in number of employees category among its peers. The total workforce of Medical Distribution industry is at this time estimated at about 116,897. SINOPHARM GROUP totals roughly 113,234 in number of employees claiming about 97% of all equities under Medical Distribution industry.
The company has Profit Margin (PM) of 0.01 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.04 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.04.

SINOPHARM GROUP 15ON Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. SINOPHARM GROUP 15ON Price Series Summation is a cross summation of SINOPHARM GROUP price series and its benchmark/peer.

About SINOPHARM GROUP Management Performance

The success or failure of an entity such as SINOPHARM GROUP 15ON often depends on how effective the management is. SINOPHARM GROUP management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of SINOPHARM management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the SINOPHARM management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. The company was founded in 2003 and is headquartered in Shanghai, the Peoples Republic of China. SINOPHARM GROUP operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 108370 people.

Complementary Tools for SINOPHARM Stock analysis

When running SINOPHARM GROUP's price analysis, check to measure SINOPHARM GROUP's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SINOPHARM GROUP is operating at the current time. Most of SINOPHARM GROUP's value examination focuses on studying past and present price action to predict the probability of SINOPHARM GROUP's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SINOPHARM GROUP's price. Additionally, you may evaluate how the addition of SINOPHARM GROUP to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments